vTv Therapeutics 
Welcome,         Profile    Billing    Logout  
 11 Products   43 Diseases  11 Products   12 Trials   305 News 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azeliragon (TTP488) / Cantex Pharma
2017-004065-27: Clinical Study to assess the Safety And Efficacy Of Investigational Medicinal Product Azeliragon (TTP488) In Patients With Mild Alzheimer's Disease who have previously completed a Clinical Trial with Azeliragon (TP488)

Not yet recruiting
3
800
Europe
Azeliragon, TTP488, Capsule, hard
vTv THERAPEUTICS LLC, vTv THERAPEUTICS LLC
MILD ALZHEIMER'S DISEASE, MILD ALZHEIMER'S DISEASE, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05815485: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Active, not recruiting
2/3
144
US
Azeliragon, Placebo
The University of Texas Medical Branch, Galveston
COVID-19
04/26
04/26
NCT05986851: Azeliragon in MGMT Unmethylated Glioblastoma

Active, not recruiting
2
30
US
Azeliragon
Cantex Pharmaceuticals, Medpace, Inc.
Glioblastoma
09/24
06/25
2022-002801-36: Azeliragon in Glioblastoma Azeliragon en Glioblastoma

Not yet recruiting
1/2
18
Europe
Azeliragon, TTP488, Capsule
Cantex Pharmaceuticals Inc., Cantex Pharmaceuticals Inc.
Newly diagnosed glioblastoma Glioblastoma de reciente diagnóstico, Glioblastoma Glioblastoma, Diseases [C] - Cancer [C04]
 
 
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
NCT05766748: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Recruiting
1/2
30
US
Azeliragon, TTP488
Cantex Pharmaceuticals
Metastatic Pancreatic Cancer
02/25
05/25
RAGE, NCT05256745: Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

Recruiting
1/2
48
US
TTP488, Azeliragon, ddAC/ddT, Dose dense doxorubicin plus cyclophosphamide, dose dense paclitaxel, TC, Docetaxel plus cyclophosphamide, TCHP, Docetaxel, carboplatin, trastuzumab, and pertuzumab, Chemotherapy regimen that includes ddAC, Dose dense doxorubicin plus cyclophosphamide
Georgetown University
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
10/25
10/25
ADORATION, NCT05789589: Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Recruiting
1/2
46
US
Azeliragon, TTP488, PF-04494700, Stereotactic radiosurgery, Corticosteroid, dexamethasone, methylprednisolone
Baptist Health South Florida, Miami Cancer Institute, Cantex Pharmaceuticals Inc.
Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
10/25
08/27
NCT05773664: Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Withdrawn
1
21
NA
Azeliragon, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Magnetic Resonance Imaging of the Brain with and without Contrast, Brain Magnetic Resonance Imaging with and without Contrast, Brain MRI, Brain MRI with and without Contrast, Head MRI with and without Contrast
City of Hope Medical Center, National Cancer Institute (NCI)
Glioblastoma, Malignant Glioma
11/24
11/24
NCT06724926: Concurrent Azeliragon With Craniospinal Irradiation

Recruiting
1
32
US
Azeliragon, CSI
NYU Langone Health
Solid Tumor, High-grade Glioma, Leptomeningeal Metastasis
01/27
01/31
NCT06831526: Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Not yet recruiting
1
12
US
Azeliragon, Temozolomide, TMZ, Radiation therapy, Surgery or LITT
Washington University School of Medicine, Cantex Pharmaceuticals
Glioblastoma
10/28
04/30
mavodelpar (REN001) / OnKure
NCT05267574 / 2021-003471-34: An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Terminated
2/3
155
Europe, Canada, RoW
REN001
Reneo Pharma Ltd
Primary Mitochondrial Myopathy
12/23
01/24
STRIDE, NCT04535609 / 2020-002855-40: An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

Completed
2
213
Europe, Canada, US, RoW
Mavodelpar, REN001, Placebo
Reneo Pharma Ltd
Primary Mitochondrial Myopathy
09/23
10/23
2018-002969-19: A study to evaluate the safety of REN001 capsules when given for 12 weeks (with option to continue treatment) to patients with mitochondrial myopathies.

Not yet recruiting
1
24
Europe
REN001, Capsule, hard
Reneo Pharma Ltd., Reneo Pharma Ltd.
Primary mitochondrial myopathy, Primary mitochondrial myopathy, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
cadisegliatin (TTP399) / vTv Therapeutics
CATT1, NCT06334133: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting
3
150
US
Cadisegliatin 800 mg QD, TTP399, Cadisegliatin 800 mg BID, Placebo
vTv Therapeutics
Diabetes Mellitus, Type 1
09/26
10/26
HPP737 / vTv Therapeutics
ChiCTR2100051725: A randomized, placebo-controlled, double-blind, multi-dose escalation phase IIa clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of oral HPP737 in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Not yet recruiting
2
48
 
HPP737 6mg, oral taken once a day ;Placebo ;HPP737 10mg, oral taken once a day ;HPP737 20mg, oral taken once a day ;HPP737 40mg, oral taken once a day
West China Hospital, Sichuan University; West China Hospital, Hengyi Biomedical Technology (Shanghai) Co., Ltd.
Chronic obstructive pulmonary disease (COPD)
 
 
NCT04714294: Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers

Recruiting
1
84
RoW
HPP737 or placebo
Newsoara Biopharma Co., Ltd.
Healthy
05/21
05/21
NCT06584058: HPP737 Substance Balance Study in Human

Not yet recruiting
N/A
8
RoW
HPP737
Newsoara Biopharma Co., Ltd.
Psoriasis
07/25
08/25
ANT-401 / Aditum Bio
No trials found
TTP273 / vTv Therapeutics
No trials found
Hexokinase II inhibitor / vTv Therapeutics
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azeliragon (TTP488) / Cantex Pharma
2017-004065-27: Clinical Study to assess the Safety And Efficacy Of Investigational Medicinal Product Azeliragon (TTP488) In Patients With Mild Alzheimer's Disease who have previously completed a Clinical Trial with Azeliragon (TP488)

Not yet recruiting
3
800
Europe
Azeliragon, TTP488, Capsule, hard
vTv THERAPEUTICS LLC, vTv THERAPEUTICS LLC
MILD ALZHEIMER'S DISEASE, MILD ALZHEIMER'S DISEASE, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05815485: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Active, not recruiting
2/3
144
US
Azeliragon, Placebo
The University of Texas Medical Branch, Galveston
COVID-19
04/26
04/26
NCT05986851: Azeliragon in MGMT Unmethylated Glioblastoma

Active, not recruiting
2
30
US
Azeliragon
Cantex Pharmaceuticals, Medpace, Inc.
Glioblastoma
09/24
06/25
2022-002801-36: Azeliragon in Glioblastoma Azeliragon en Glioblastoma

Not yet recruiting
1/2
18
Europe
Azeliragon, TTP488, Capsule
Cantex Pharmaceuticals Inc., Cantex Pharmaceuticals Inc.
Newly diagnosed glioblastoma Glioblastoma de reciente diagnóstico, Glioblastoma Glioblastoma, Diseases [C] - Cancer [C04]
 
 
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
NCT05766748: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Recruiting
1/2
30
US
Azeliragon, TTP488
Cantex Pharmaceuticals
Metastatic Pancreatic Cancer
02/25
05/25
RAGE, NCT05256745: Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

Recruiting
1/2
48
US
TTP488, Azeliragon, ddAC/ddT, Dose dense doxorubicin plus cyclophosphamide, dose dense paclitaxel, TC, Docetaxel plus cyclophosphamide, TCHP, Docetaxel, carboplatin, trastuzumab, and pertuzumab, Chemotherapy regimen that includes ddAC, Dose dense doxorubicin plus cyclophosphamide
Georgetown University
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
10/25
10/25
ADORATION, NCT05789589: Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Recruiting
1/2
46
US
Azeliragon, TTP488, PF-04494700, Stereotactic radiosurgery, Corticosteroid, dexamethasone, methylprednisolone
Baptist Health South Florida, Miami Cancer Institute, Cantex Pharmaceuticals Inc.
Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
10/25
08/27
NCT05773664: Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Withdrawn
1
21
NA
Azeliragon, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Magnetic Resonance Imaging of the Brain with and without Contrast, Brain Magnetic Resonance Imaging with and without Contrast, Brain MRI, Brain MRI with and without Contrast, Head MRI with and without Contrast
City of Hope Medical Center, National Cancer Institute (NCI)
Glioblastoma, Malignant Glioma
11/24
11/24
NCT06724926: Concurrent Azeliragon With Craniospinal Irradiation

Recruiting
1
32
US
Azeliragon, CSI
NYU Langone Health
Solid Tumor, High-grade Glioma, Leptomeningeal Metastasis
01/27
01/31
NCT06831526: Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Not yet recruiting
1
12
US
Azeliragon, Temozolomide, TMZ, Radiation therapy, Surgery or LITT
Washington University School of Medicine, Cantex Pharmaceuticals
Glioblastoma
10/28
04/30
mavodelpar (REN001) / OnKure
NCT05267574 / 2021-003471-34: An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Terminated
2/3
155
Europe, Canada, RoW
REN001
Reneo Pharma Ltd
Primary Mitochondrial Myopathy
12/23
01/24
STRIDE, NCT04535609 / 2020-002855-40: An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

Completed
2
213
Europe, Canada, US, RoW
Mavodelpar, REN001, Placebo
Reneo Pharma Ltd
Primary Mitochondrial Myopathy
09/23
10/23
2018-002969-19: A study to evaluate the safety of REN001 capsules when given for 12 weeks (with option to continue treatment) to patients with mitochondrial myopathies.

Not yet recruiting
1
24
Europe
REN001, Capsule, hard
Reneo Pharma Ltd., Reneo Pharma Ltd.
Primary mitochondrial myopathy, Primary mitochondrial myopathy, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
cadisegliatin (TTP399) / vTv Therapeutics
CATT1, NCT06334133: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting
3
150
US
Cadisegliatin 800 mg QD, TTP399, Cadisegliatin 800 mg BID, Placebo
vTv Therapeutics
Diabetes Mellitus, Type 1
09/26
10/26
HPP737 / vTv Therapeutics
ChiCTR2100051725: A randomized, placebo-controlled, double-blind, multi-dose escalation phase IIa clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of oral HPP737 in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Not yet recruiting
2
48
 
HPP737 6mg, oral taken once a day ;Placebo ;HPP737 10mg, oral taken once a day ;HPP737 20mg, oral taken once a day ;HPP737 40mg, oral taken once a day
West China Hospital, Sichuan University; West China Hospital, Hengyi Biomedical Technology (Shanghai) Co., Ltd.
Chronic obstructive pulmonary disease (COPD)
 
 
NCT04714294: Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers

Recruiting
1
84
RoW
HPP737 or placebo
Newsoara Biopharma Co., Ltd.
Healthy
05/21
05/21
NCT06584058: HPP737 Substance Balance Study in Human

Not yet recruiting
N/A
8
RoW
HPP737
Newsoara Biopharma Co., Ltd.
Psoriasis
07/25
08/25
ANT-401 / Aditum Bio
No trials found
TTP273 / vTv Therapeutics
No trials found
Hexokinase II inhibitor / vTv Therapeutics
No trials found

Download Options